Multaq (dronedarone) is a prescription drug used to reduce the risk of hospitalization in certain adults with atrial fibrillation (AFib). Multaq can cause side effects that range from mild to serious.

A trial of the drug Multaq, used to treat abnormal heart rhythm, has been halted over concerns of other heart-related side effects, drug maker Sanofi announced Thursday. Multaq, also known as ...

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended new restriction on dronedarone (Multaq), Sanofi's embattled and controversial antiarrhythmic drug.

Multaq (dronedarone) is a brand-name oral tablet that’s prescribed to reduce a certain risk associated with atrial fibrillation. Multaq has interactions with some other drugs and certain supplements.

The PALLAS trial of dronedarone (Multaq) for permanent AF has been stopped early, according to a press release (below) issued by Sanofi. PALLAS (Permanent Atrial fibriLLAtion outcome Study using ...

Multaq(R) Approved to Reduce the Risk of Cardiovascular Hospitalizationin Patients With Atrial Fibrillation or Atrial Flutter. PARIS, July 2 /PRNewswire/ -- - U.S Commercial Launch Planned for the ...

Sanofi has been counting on Multaq to help fill in the gaps as it loses patent protection on some key products. Sanofi's (NYSE: SNY) Multaq has stumbled again. The company stopped a trial of the ...

STOCKHOLM, Aug 29 (Reuters) - Sanofi-Aventis's new heart rhythm drug Multaq should be considered as a first-line treatment option for patients with atrial fibrillation, a common arrhythmia, according ...

WASHINGTONWASHINGTON — Federal health officials said Monday they have added new safety warnings to the heart rhythm drug Multaq, after a company study by Sanofi linked the tablet to higher rates of ...

PARIS, August 29, 2010 /PRNewswire/ -- Sanofi aventis (EURONEXT: SAN and NYSE: SNY) announced today that the European Society of Cardiology (ESC) 2010 new Guidelines for the Management of Atrial ...

Before Sanofi-Aventis launched its heart drug Multaq, some analysts estimated revenues would top €3 billion. But 10 weeks into the launch, Multaq looks like a much more modest affair, according to a ...